CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Cell cycle progression, including genome duplication, is orchestrated by cyclin-dependent kinases (CDKs). CDK activation depends on phosphorylation of their T-loop by a CDK-activating kinase (CAK). In animals, the only known CAK for CDK2 and CDK1 is cyclin H-CDK7, which is constitutively active. Therefore, the critical activation step is dephosphorylation of inhibitory sites by Cdc25 phosphatases rather than unrestricted T-loop phosphorylation. Homologous CDK4 and CDK6 bound to cyclins D are master integrators of mitogenic/oncogenic signaling cascades by initiating the inactivation of the central oncosuppressor pRb and cell cycle commitment at the restriction point. Unlike the situation in CDK1 and CDK2 cyclin complexes, and in contrast to the weak but constitutive T177 phosphorylation of CDK6, we have identified the T-loop phosphorylation at T172 as the highly regulated step determining CDK4 activity. Whether both CDK4 and CDK6 phosphorylations are catalyzed by CDK7 remains unclear. To answer this question, we took a chemical-genetics approach by using analogue-sensitive CDK7(as/as) mutant HCT116 cells, in which CDK7 can be specifically inhibited by bulky adenine analogs. Intriguingly, CDK7 inhibition prevented activating phosphorylations of CDK4/6, but for CDK4 this was at least partly dependent on its binding to p21 (cip1) . In response to CDK7 inhibition, p21-binding to CDK4 increased concomitantly with disappearance of the most abundant phosphorylation of p21, which we localized at S130 and found to be catalyzed by both CDK4 and CDK2. The S130A mutation of p21 prevented the activating CDK4 phosphorylation, and inhibition of CDK4/6 and CDK2 impaired phosphorylations of both p21 and p21-bound CDK4. Therefore, specific CDK7 inhibition revealed the following: a crucial but partly indirect CDK7 involvement in phosphorylation/activation of CDK4 and CDK6; existence of CDK4-activating kinase(s) other than CDK7; and novel CDK7-dependent positive feedbacks mediated by p21 phosphorylation by CDK4 and CDK2 to sustain CDK4 activation, pRb inactivation, and restriction point passage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Such deregulation is crucial for various oncogenic transformation processes [20–22] suggesting that many cancer cells are addicted to high CDK4/6 activity [19,23–25].”
Backgroundp21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“CDK4/6 activity is deregulated through various mechanisms in many human tumors [18,19].”
BackgroundNew functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · cited 1×
“CDK4/6 activity is deregulated through various mechanisms in many human tumors [18,19].”
BackgroundCheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 1×
“As generally observed in unperturbed cell cycles [3,10,58], p21-bound CDK4/6 was largely active in response to serum stimulation, and here again its activity was inhibited by 1-NMPP1 treatment (Figure 1C).”
BackgroundSherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980 · cited 1×
“signaling [1–3].”
A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase
Fisher, R. P., & Morgan, D. O. (1994) · Cell · doi:10.1016/0092-8674(94)90535-5 · Cited by 655
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513 · cited 1×
“PD0332991 is a specific inhibitor of CDK4 and CDK6 and does not inhibit CDK2 and the proliferation of pRb-negative cells [27,70].”
BackgroundPuyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · cited 2×
“Such deregulation is crucial for various oncogenic transformation processes [20–22] suggesting that many cancer cells are addicted to high CDK4/6 activity [19,23–25].”
BackgroundOncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358 · cited 1×
“This would provide a rationale for treatments that combine inhibitory drugs targeting oncogenic signaling pathways and CDKs, as suggested recently [88].”
BackgroundThe Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342 · cited 2×
“Such deregulation is crucial for various oncogenic transformation processes [20–22] suggesting that many cancer cells are addicted to high CDK4/6 activity [19,23–25].”
BackgroundCdk-Inhibitory Activity and Stability of p27 Are Directly Regulated by Oncogenic Tyrosine Kinases
Grimmler, M., Wang, Y., Mund, T., Cilenšek, Z., Keidel, E.-M., Waddell, M. B., Jäkel, H., Kullmann, M., Kriwacki, R. W., & Hengst, L. (2007) · Cell · doi:10.1016/j.cell.2006.11.047 · Cited by 337
Self-citationCyclin-Binding Motifs Are Essential for the Function of p21 CIP1
Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., & Dutta, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4673 · Cited by 320 · cited 4×
“p21 interacts with cyclin-CDK complexes through two cyclin-binding sites, designated Cy1 and Cy2, respectively located in the N and the C terminus, and a single CDK-binding site (K) closer to the central region [64].”
BackgroundInfluentialBlain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225 · cited 1×
“PD0332991 is a specific inhibitor of CDK4 and CDK6 and does not inhibit CDK2 and the proliferation of pRb-negative cells [27,70].”
BackgroundCR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Wang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134 · cited 1×
“A CDK4/6 inhibitor (PD0332991 [24–29]) that effectively halts tumor growth in preclinical models and in patients is being tested in phase II clinical trials on various pRb-proficient chemotherapy-resistant cancers.”
BackgroundXpd/Ercc2 regulates CAK activity and mitotic progression
Chen, J., Larochelle, S., Li, X., & Suter, B. (2003) · Nature · doi:10.1038/nature01746 · Cited by 127 · cited 3×
“In K7AS cells, the association of CDK7 and XPD [69] with cyclin H was not modified by these treatments, although MAT1 association was slightly increased by serum stimulation (Figure S10A).”
BackgroundInfluentialAnalysis of Wild-Type and Mutant p21 WAF-1 Gene Activities
Lin, J., Reichner, C., Wu, X., & J. Levine, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1786 · Cited by 111 · cited 1×
“In the case of cyclin D1-CDK4, the interaction of p21 with CDK4 and the resulting inhibition of its activity have been reported to depend mainly on both the N-terminal Cy1 cyclin-binding motif and the K CDK-binding site [64,81].”
Background
Cited by
Promotion of Myoblast Differentiation by Fkbp5 via Cdk4 Isomerization
Ruiz-Estevez, M., Staats, J., Paatela, E., Munson, D., Katoku-Kikyo, N., Yuan, C., Asakura, Y., Hostager, R., Kobayashi, H., Asakura, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.006 · Cited by 39
“…level of Cdk4 does not drastically fluctuate during the cell cycle; its activity is controlled by at least three steps of post-translational regulation, although the exact order of events has not been firmly established (Bisteau et al., 2013; Bockstaele et al., 2009; Schachter et al., 2013).”
BackgroundmiR-150 inhibits terminal erythroid, proliferation and differentiation.
Sun, Z., Wang, Y., Han, X., Zhao, X., Peng, Y., Li, Y., Peng, M., Song, J., Wu, K., Sun, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5824 · Cited by 32
Peptidylprolylisomerases, Protein Folders, or Scaffolders? The Example of FKBP51 and FKBP52
Rein, T. (2020) · BioEssays · doi:10.1002/bies.201900250 · Cited by 25
Metadata
- Authors
- Bisteau, X., Paternot, S., Colleoni, B., Ecker, K., Coulonval, K., De Groote, P., Declercq, W., Hengst, L., & Roger, P. P.
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-30
- Volume
- 9
- Issue
- 5
- Pages
- e1003546
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W1964471916
- Cited by
- 65
- References
- 22
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.